| Name | Title | Contact Details |
|---|
Chiral Quest is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ReviveRX is a leading licensed mail-order pharmacy specializing in generic and compounded medications. Our compounds are expertly crafted in USP-certified clean rooms at our Houston headquarters, ensuring the highest quality standards. We work closely with best-in-class pharmacists, scientists, healthcare providers, and pharmaceutical manufacturers to provide high-quality, dependable products to our patients and clinic partners.
PDL manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. To acquire new income generating assets, PDL provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. PDL has invested approximately $780 million to date. PDL evaluates its investments based on the quality of the income generating assets and potential returns on investment. PDL is currently focused on intellectual property asset management, acquiring new income generating assets and maximizing value for its shareholders. The Company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL was founded in 1986 and is headquartered in Incline Village, Nevada. PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases for which it receives significant royalty revenue.
PCI Pharma Services is a global leader in Contract Development and Manufacturing Organization (CDMO) services, offering integrated solutions for drug development, manufacturing, and packaging. The company focuses on innovation and patient-centric approaches, supporting pharmaceutical and biopharmaceutical companies at various stages of drug development and commercialization. With 30 Good Manufacturing Practice (GMP) facilities across seven countries, PCI employs over 4,300 people dedicated to delivering life-changing therapies. The company provides a comprehensive range of services, including drug development and manufacturing for various dosage forms, advanced drug delivery systems, and complex packaging solutions. PCI also manages storage, distribution, and logistics to support the pharmaceutical supply chain and offers clinical trial supply chain management. Committed to growth, PCI has made significant investments, including a $100 million expansion in New England to enhance its global capacity and capabilities.
Quantapore`s novel, high throughput, massively parallel sequencer will allow rapid, affordable and sensitive sequencing of entire genomes. This desktop system will address the need for efficient sequencing. Revenues will be garnered by seeding units into customer facilities, and then by the sale of consumable cartridges; providing rapid growth as the installed base and customer utilization increases.